Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD62L Depleted DLI with Haploidentical HSCT
NCT06034535Phase 2Recruiting
- Sponsor
- Hong Kong Children’s Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CD62L depleted donor lymphocyte infusion in hematologic malignancy, Hematologic disease, sponsored by Hong Kong Children’s Hospital. Started Sep 2023; status: recruiting.
02
Drugs
CD62L depleted donor lymphocyte infusion
03
Conditions
hematologic malignancyHematologic disease
Beyond the preview
Go deeper on NCT06034535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034535.